NCT00922012

Brief Summary

In 1995 the National Institutes of Health-National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) workshop reached a consensus on the definition and classification of prostatitis syndromes.The commonest and yet most poorly understood of these prostatitis syndromes is category III or chronic pelvic pain syndrome (CPPS). It has been shown that, while men with CPPS have significantly higher leukocyte counts in urine and expressed prostatic secretions compared with age matched controls, inflammation and infection do not necessarily correlate with symptom severity. The lack of a direct relationship between inflammation and symptoms is supported through studies of prostate histopathology, in which moderate or severe inflammation was identified in only 5% of men with CPPS.Conventional treatment has focused on long, empirical courses of expensive broad-spectrum antibiotics, mostly of the quinolone class, with or without the concomitant use of an α-blocker and anti-inflammatory agents. At the turn of the 19th century stimulation with electrical current and changing magnetic fields was used to treat surface conditions associated with intractable pain, such as painful malignant ulcers. The analgesic benefits of pulsed electromagnetic fields for relieving pelvic pain has been investigated in women with tissue trauma and chronic refractory pelvic pain.Despite its uncertain etiology there is some evidence that the symptom complex found in CPPS may be founded at least in part in pelvic floor muscular dysfunction and/or neurogenic hypersensitivity/inflammation. We hypothesized that the application of a electromagnetic stimulation to the perineum of the subject may result in neural excitation and pelvic floor muscle stimulation to a degree that breaks the cycle of tonic muscular spasm and neural hypersensitivity/inflammation, thereby, restoring more normal pelvic floor muscular activity.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2007

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2007

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2009

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

June 16, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 17, 2009

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2009

Completed
Last Updated

May 12, 2011

Status Verified

May 1, 2011

Enrollment Period

1.3 years

First QC Date

June 16, 2009

Last Update Submit

May 10, 2011

Conditions

Keywords

Electromagnetic Stimulation TherapyChronic ProstatitisChronic Pelvic Pain Syndrome

Outcome Measures

Primary Outcomes (1)

  • Change in NIH-CPSI total and pain score

    24 weeks after treatment

Secondary Outcomes (1)

  • Changes in - NIH-CPSI urinary, QoL impact score - Qmax/PVR - frequency/24hrs - urgency episode/24hrs - Patient perception of treatment benefit, satisfaction, willingness to continue - Goal achievement - Patient's Perception of Symptom Improvement

    24 weeks of treatment

Study Arms (1)

Electromagnetic stimulation

EXPERIMENTAL

Electromagnetic stimulation therapy

Device: Electromagnetic Stimulation Therapy

Interventions

Electromagnetic Stimulation Therapy for 24 weeks

Electromagnetic stimulation

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18
  • NIDDK category III chronic prostatitis/chronic pelvic pain syndrome
  • Symptom duration ≥ 3 months
  • The sum of 1 or 2 domain of NIH-CPSI ≥ 1 point
  • The sum NIH-CPSI ≥ 15 points

You may not qualify if:

  • History of prostate cancer
  • History of pelvic irradiation
  • History of transurethral surgery
  • Urinary tract infection within 6 months to screening
  • Postvoid urine volume ≥ 150ml
  • Interstitial cystitis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Samsung Medical Center

Seoul, 135-710, South Korea

Location

Study Officials

  • Kyu-Sung Lee, Ph.D

    Samsung Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

June 16, 2009

First Posted

June 17, 2009

Study Start

November 1, 2007

Primary Completion

March 1, 2009

Study Completion

December 1, 2009

Last Updated

May 12, 2011

Record last verified: 2011-05

Locations